Small cap healthcare stocks surge to billion-dollar plays
The Australian Financial Review mentioned that Starpharma was in a group of small cap biotech stocks in stage two trials that investors are closely in the next few years.
To read the full article, click here (paywall)
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Starpharma today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar®) and olaparib (Lynparza®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer xenograft model.
Starpharma’s VivaGel® BV regulatory approvals continue in Asia
|
Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August. |
Read the full news coverage here.
VivaGel® BV regulatory approvals continue in Asia
Starpharma today announced that it has received a further regulatory approval in an Asian country for VivaGel® BV. This approval follows multiple country approvals in the region as previously announced on 15 August 2019. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel.